Gilead Sciences (GILD) Stake Lessened by Swiss National Bank

Swiss National Bank lowered its position in shares of Gilead Sciences (NASDAQ:GILD) by 12.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,363,224 shares of the biopharmaceutical company’s stock after selling 605,800 shares during the period. Swiss National Bank’s holdings in Gilead Sciences were worth $328,943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Heritage Wealth Advisors increased its holdings in Gilead Sciences by 2.5% in the 4th quarter. Heritage Wealth Advisors now owns 26,523 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 642 shares during the last quarter. Hanson & Doremus Investment Management grew its stake in shares of Gilead Sciences by 35.7% in the fourth quarter. Hanson & Doremus Investment Management now owns 2,461 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 648 shares in the last quarter. Griffin Asset Management Inc. grew its stake in shares of Gilead Sciences by 2.5% in the fourth quarter. Griffin Asset Management Inc. now owns 27,160 shares of the biopharmaceutical company’s stock worth $1,946,000 after acquiring an additional 650 shares in the last quarter. First Capital Advisors Group LLC. grew its stake in shares of Gilead Sciences by 9.1% in the fourth quarter. First Capital Advisors Group LLC. now owns 7,857 shares of the biopharmaceutical company’s stock worth $563,000 after acquiring an additional 653 shares in the last quarter. Finally, Wedbush Securities Inc. grew its stake in shares of Gilead Sciences by 1.0% in the fourth quarter. Wedbush Securities Inc. now owns 65,102 shares of the biopharmaceutical company’s stock worth $4,664,000 after acquiring an additional 660 shares in the last quarter. Institutional investors and hedge funds own 78.15% of the company’s stock.

In related news, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $78.69, for a total value of $1,967,250.00. Following the completion of the sale, the executive vice president now directly owns 69,426 shares of the company’s stock, valued at $5,463,131.94. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 14,435 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $81.54, for a total transaction of $1,177,029.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 241,102 shares of company stock valued at $18,237,884. 1.30% of the stock is owned by corporate insiders.

GILD has been the subject of several research reports. Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target for the company. in a research note on Wednesday, January 17th. Wells Fargo upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $79.02 to $96.00 in a research note on Tuesday, January 16th. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, January 18th. Citigroup upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $88.80 to $76.00 in a research note on Tuesday, January 30th. Finally, ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $88.14.

Gilead Sciences opened at $66.16 on Friday, Marketbeat Ratings reports. The firm has a market cap of $85.65 billion, a PE ratio of 7.73, a PEG ratio of -5.71 and a beta of 1.19. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $89.54. The company has a debt-to-equity ratio of 1.53, a current ratio of 3.45 and a quick ratio of 3.36.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.67 by ($0.19). Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The firm had revenue of $5.09 billion for the quarter, compared to analysts’ expectations of $5.40 billion. During the same period last year, the firm posted $2.23 earnings per share. Gilead Sciences’s revenue for the quarter was down 21.8% on a year-over-year basis. sell-side analysts forecast that Gilead Sciences will post 5.75 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Investors of record on Friday, June 15th will be given a $0.57 dividend. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $2.28 dividend on an annualized basis and a yield of 3.45%. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply